Hofseth BioCare ASA (HBC.OL)
NOK 1.41
(-23.37%)
NOK 1.41
(-23.37%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 156.04 Million NOK | -54.43% |
| 2022 | 157.13 Million NOK | 10.92% |
| 2021 | 141.66 Million NOK | 16.28% |
| 2020 | 121.82 Million NOK | 37.57% |
| 2019 | 88.55 Million NOK | -2.53% |
| 2018 | 90.85 Million NOK | 20.3% |
| 2017 | 75.52 Million NOK | 17.54% |
| 2016 | 64.25 Million NOK | -23.81% |
| 2015 | 84.33 Million NOK | 21.23% |
| 2014 | 69.56 Million NOK | -19.65% |
| 2013 | 86.56 Million NOK | 44.05% |
| 2012 | 60.09 Million NOK | 140.0% |
| 2011 | 25.04 Million NOK | 91.5% |
| 2010 | 13.07 Million NOK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 23.01 Million NOK | 45.27% |
| 2024 Q1 | 24.88 Million NOK | 32.69% |
| 2023 Q2 | 40.96 Million NOK | 2.63% |
| 2023 Q4 | 18.75 Million NOK | -55.55% |
| 2023 Q3 | 42.18 Million NOK | 2.98% |
| 2023 FY | 71.6 Million NOK | -54.43% |
| 2023 Q1 | 39.92 Million NOK | -3.18% |
| 2022 Q4 | 41.23 Million NOK | 6.11% |
| 2022 Q3 | 38.85 Million NOK | 11.4% |
| 2022 Q2 | 34.88 Million NOK | -17.28% |
| 2022 FY | 157.13 Million NOK | 10.92% |
| 2022 Q1 | 42.16 Million NOK | 7.73% |
| 2021 Q2 | 32.25 Million NOK | -3.66% |
| 2021 Q1 | 33.47 Million NOK | -5.74% |
| 2021 Q3 | 36.79 Million NOK | 14.08% |
| 2021 Q4 | 39.13 Million NOK | 6.37% |
| 2021 FY | 141.66 Million NOK | 16.28% |
| 2020 FY | 121.82 Million NOK | 37.57% |
| 2020 Q1 | 28.26 Million NOK | 6.47% |
| 2020 Q3 | 32.57 Million NOK | 27.92% |
| 2020 Q2 | 25.46 Million NOK | -9.92% |
| 2020 Q4 | 35.51 Million NOK | 9.03% |
| 2019 Q4 | 26.55 Million NOK | 45.51% |
| 2019 Q2 | 20.68 Million NOK | -10.32% |
| 2019 Q1 | 23.07 Million NOK | -3.57% |
| 2019 Q3 | 18.24 Million NOK | -11.8% |
| 2019 FY | 88.55 Million NOK | -2.53% |
| 2018 Q2 | 21.05 Million NOK | -8.71% |
| 2018 FY | 90.85 Million NOK | 20.3% |
| 2018 Q1 | 23.06 Million NOK | 19.99% |
| 2018 Q4 | 23.92 Million NOK | 4.9% |
| 2018 Q3 | 22.8 Million NOK | 8.32% |
| 2017 Q3 | 18.29 Million NOK | -3.55% |
| 2017 FY | 75.52 Million NOK | 17.54% |
| 2017 Q4 | 19.22 Million NOK | 5.08% |
| 2017 Q1 | 19.04 Million NOK | -12.29% |
| 2017 Q2 | 18.96 Million NOK | -0.38% |
| 2016 Q4 | 21.7 Million NOK | 77.49% |
| 2016 FY | 64.25 Million NOK | -23.81% |
| 2016 Q2 | 12.29 Million NOK | -31.73% |
| 2016 Q1 | 18.01 Million NOK | -53.53% |
| 2016 Q3 | 12.23 Million NOK | -0.55% |
| 2015 Q3 | 16.23 Million NOK | 5.3% |
| 2015 Q4 | 38.76 Million NOK | 138.79% |
| 2015 FY | 84.33 Million NOK | 21.23% |
| 2015 Q1 | 13.91 Million NOK | -27.39% |
| 2015 Q2 | 15.41 Million NOK | 10.77% |
| 2014 FY | 69.56 Million NOK | -19.65% |
| 2014 Q4 | 19.16 Million NOK | 9.8% |
| 2014 Q3 | 17.45 Million NOK | 34.65% |
| 2014 Q2 | 12.96 Million NOK | -35.08% |
| 2014 Q1 | 19.97 Million NOK | -22.13% |
| 2013 Q1 | 20.4 Million NOK | 4.57% |
| 2013 Q2 | 18.83 Million NOK | -7.69% |
| 2013 Q3 | 21.68 Million NOK | 15.11% |
| 2013 Q4 | 25.64 Million NOK | 18.3% |
| 2013 FY | 86.56 Million NOK | 44.05% |
| 2012 Q1 | 15.12 Million NOK | 89.97% |
| 2012 Q3 | 11.18 Million NOK | -23.77% |
| 2012 Q4 | 19.51 Million NOK | 74.43% |
| 2012 FY | 60.09 Million NOK | 140.0% |
| 2012 Q2 | 14.67 Million NOK | -3.0% |
| 2011 Q1 | 5.97 Million NOK | -23.91% |
| 2011 Q4 | 7.96 Million NOK | 34.93% |
| 2011 FY | 25.04 Million NOK | 91.5% |
| 2011 Q3 | 5.9 Million NOK | 13.48% |
| 2011 Q2 | 5.2 Million NOK | -12.99% |
| 2010 Q4 | 7.85 Million NOK | 433.86% |
| 2010 FY | 13.07 Million NOK | 0.0% |
| 2010 Q3 | 1.47 Million NOK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Arctic Bioscience AS | -5730.00 NOK | 2723363.525% |
| Aqua Bio Technology ASA | 18.46 Million NOK | -745.071% |
| ArcticZymes Technologies ASA | 97.26 Million NOK | -60.427% |
| BerGenBio ASA | 192.17 Million NOK | 18.801% |
| PCI Biotech Holding ASA | 25.23 Million NOK | -518.457% |
| Thor Medical ASA | 7.16 Million NOK | -2079.067% |
| Ultimovacs ASA | 215.73 Million NOK | 27.669% |